Metabolomic Technologies Inc. - Product Pipeline Analysis - New Market Research Report
Metabolomic Technologies Inc. (MTI) focuses on the development of novel, patented, metabolomic-based, diagnostic tests to detect adenomatous polyps and colorectal cancer. The company's product portfolio consists of ColoDx, a diagnostic system engeneered to detect colorectal cancer based on a unique fingerprint of metabolites; and PolypDx, a diagnostic system that is designed to detect colonic adenomatous polyps. MTI also focuses on the development of other products, namely, BreastDx, a diagnostic for breast cancer, ProstateDx, a diagnostic for prostate cancer, CeliacDx, a...
View full press release